Carolina Clinical Research conducts Phase III clinical trials in several areas. Working closely with drug manufactures and study sponsors, we ensure the safe, comfortable, and effective administration of clinical trial medications.
While we may have trials covering several clinical areas, our principal investigators and clinical staff specialize in the following study areas:
Pulmonary Disorders, including COPD and Asthma
Infectious Diseases , including COVID-19
Currently, Carolina Clinical Research is enrolling participants in the following studies:
ACTIV-2: A Study for Outpaitents with COVID-19
RPL554-CO-302: A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients with COPD
EFC16725: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)
Eligible study participants can recieve study treatment and medications at no cost, and may be eligible for additional compensation, including study stipends, expense reimbursements, and free transportation.
Click Here for EFC16725 trial information
Click Here for RPL554 trial information